Comments

MediPharm Labs

MEDIFOTCQB
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers

MediPharm Labs (MEDIF) Forecast

NewsEarningsMediPharm Labs (MEDIF) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

MediPharm Labs (OTC:MEDIF) Stock Quotes, Forecast and News Summary

MediPharm Labs Stock (OTC: MEDIF) stock price, news, charts, stock research, profile.

Open-
Close-
Volume / Avg.0 / 139.40K
Day Range- - -
52 Wk Range0.04 - 0.07
Market Cap$17.91M
P/E Ratio-
Dividend Yield-
ExchangeOTC
RSI
0
Short Interest-
Days to Cover2.63

Recent News

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). "We are very pleased with our Q2 results, showcasing substantial improvements in both revenue and profitability," David Pidduck, the company's CEO, said. "The strategic initiatives implemented, including cost reductions and operational efficiencies, are yielding positive results. We are particularly encouraged by the continued growth in our international sales and the progress in innovation of non-combustible cannabis formats."
Jelena Martinovic
This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now
Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a cannabis operator with vertical operations in Arizona and Ohio, said it will release its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, Aug. 20, 2024. A conference call and webcast will take place on the same day at 08:00 am Eastern Time. Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) will report earnings results for its second quarter ended June 30, 2024, on Thursday, Aug. 15, 2024, before the financial markets open.Cannabinoids-focused MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, Aug. 14, 2024. A conference call and audio webcast will take place the same day at 8:30 am Eastern Time.
Jelena Martinovic

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Open-
Close-
Volume / Avg.0 / 139.40K
Day Range- - -
52 Wk Range0.04 - 0.07
Market Cap$17.91M
P/E Ratio-
Dividend Yield-
ExchangeOTC
RSI
0
Short Interest-
Days to Cover2.63

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
MEDIF

FAQ

Q

How do I buy MediPharm Labs (MEDIF) stock?

A

You can purchase shares of MediPharm Labs (OTCQB:MEDIF) through any online brokerage.

View our list of the best stock brokerages

Q

Who are MediPharm Labs (MEDIF) competitors?

A

There are no as such competitors for MediPharm Labs.

Q

What is the forecast, or price target, for MediPharm Labs (MEDIF) stock?

A

There is no analysis for MediPharm Labs to provide a consensus price target.

Q

What is the current price for MediPharm Labs (MEDIF)?

A

The stock price for MediPharm Labs (OTCQB: MEDIF) is $0.043572 last updated December 24, 2024 at 12:54 PM EST.

Q

Does MediPharm Labs (MEDIF) pay a dividend?

A

There are no upcoming dividends for MediPharm Labs.

Q

When is MediPharm Labs (OTCQB:MEDIF) reporting earnings?

A

MediPharm Labs’s Q4 earnings are confirmed for Wednesday, March 26, 2025.

Q

Is MediPharm Labs (MEDIF) going to split?

A

There is no upcoming split for MediPharm Labs.

Q

What sector and industry does MediPharm Labs (MEDIF) operate in?

A

MediPharm Labs is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the OTCQB.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved